Home > Back to Publisher > Report Information

Integrating Genomics: The Next Generation

Business Insights
February 1, 1999
124 Pages - SKU: RET26

Abstract Table of Contents Search inside this report Related Reports Buy by the Section

Integrating Genomics: The Next Generation

Although its possibilities have not yet been fully realised, experts view genomics as pivotal to improving innovation in the drug discovery process. How will genomics impact on drug R&D? What are the key genomic technologies being used? Which companies are the most active in genomic research? How could pharmacogenomics reshape the healthcare market in the future? Based upon our exclusive primary research with over 50 key opinion leaders, this report provides the vital strategic insight you need to: Identify the basic principles behind the main genomic technologies and how they can improve drug R&D and disease management Understand how the business strategies of key genomics companies are evolving to meet the needs of both their internal research departments and also their external clients Evaluate the impact of genomics and pharmacogenomics into the 21st century.

Executive summary

Introduction
Genomic research: understanding the technology
Current applications
Key players in genomic research
Future issues

Chapter 1 Introduction

Summary
Current status of R&D productivity
- The importance of R&D to the pharmaceutical industry
- R&D expenditure
- R&D timescale

Chapter 2 Genomic research: understanding the technology

Summary
Introduction
Target identification
- Genome mapping
- Positional cloning
- Random sequencing
- Genetics of model organisms
- Two-hybrid assay
- Hybridisation on a chip
- Differential display
- Massively Parallel Signature Sequencing (MPSS)
- 2-D gel electrophoresis
Target validation/Assay Development
- Gene knockouts
- Cellular assays

Chapter 3 Current applications

Summary
Introduction
Target identification
- Positional cloning
- Random sequencing
- Proteomics
- Applying bioinformatics
- Initial functional analysis
Target validation
- Animal models
- Cellular assays
- Antisense RNA and ribozymes
Assay development
- Cellular assays
- Genetically-modified model organisms
Genomics and the preclinical stage
Genetic variation and clinical development
- Pharamcogenomics
- Applying pharmacogenomics
- Pharmacogenmics and clinical testing
- Genetic testing for disease

Chapter 4 Key players in genomic research

Summary
Introduction
- Drivers to expanding technology platforms
Incyte Pharmaceuticals
- The use of DNA microarrays
- Adding further value to the databases
- Developing diagnostic tests
Axys Pharmaceuticals
Aurora Biosciences
- Future growth using its proprietary UHTSS
Affymetrix
- Research programmes
Millennium Pharmaceuticals
- Millennium's subsidiaries and their corporate alliances
Myriad Genetics
- Myriad's products
- Myriad's collaborations
Consolidation within the biotechnology sector
Role of pharmaceutical companies
- Drivers of outsourcing
- Contracting vs alliances
- Alliances vs acquisitions
- Differences in EU and US strategies
- Outsourcing genomic research
- Managing a diverse portfolio of research projects
- Investment patterns by leading pharmaceuticals

Chapter 5 Future issues regarding Genomics

Summary
Impact on drug research
- Target identification
- Target validation
- Effect on preclinical development
Impact on drug development
- Effect on clinical development
Impact on disease management
- Genetic testing of disease
- The effect of pharmcogenomics
New market opportunities
- Rise of diagnostic testing
- Designer drugs

Chapter 6 Appendix

Glossary
References
Index

List of Figures

Figure 1.1: Ethical pharmaceutical R&D expenditure for US-based companies, 1980-1998
Figure 1.2: Resource allocation in the research and development process, 1996
Figure 1.3: Technologies and applications in the early stages of drug discovery
Figure 1.4: Opportunities for generating revenues from genomics
Figure 2.5: Generating a genome map
Figure 2.6: Positional cloning
Figure 2.7: Mechanics of the two-hybrid assay
Figure 2.8: Gene chips
Figure 2.9: Methodology behind differential display
Figure 3.10: Competitive assessment of key technologies
Figure 4.12: Stages of drug discovery covered by selected companies' technologies
Figure 4.13: Drivers to expanding technology platforms
Figure 4.14: Incyte's products, technologies and corporate activities
Figure 4.15: Axys's products and technologies
Figure 4.16: Aurora's products and technologies
Figure 4.17: Affymetrix's products and technologies
Figure 4.18: Development of Affymetrix's services and products
Figure 4.19: Millennium's products and technologies
Figure 4.20: Myriad's products and technologies
Figure 5.21: The impact of drug discovery technologies on reducing development time

List of Tables

Table 1.1: Drug development timescale in US, 1960-1996
Table 1.2: Efficiency of the drug development process, 1998
Table 1.3: Competitive assessment of key technologies
Table 3.4: Corporate collaborations in genomics, 1998
Table 4.5: Selected research consortiums, 1998
Table 4.6: Selected alliances established by leading pharmaceutical companies
Table 5.7: Types and uses of genetic diagnostic tests

Integrating Genomics: The Next Generation

Share this report

Other tasks

Research Assistance

Related Markets

Antisense & RNAi Technology Reports

Free Alert Me service